10-Q: ProMIS Neurosciences Reports Q2 2024 Results, Provides Update on Clinical Programs and Recent Financing

ProMIS Neurosciences reported its second quarter 2024 financial results, highlighted by progress in its PMN310 clinical trial and a recent $30.3 million private placement.

Summary

• ProMIS Neurosciences reported a net loss of $2.6 million for the three months ended June 30, 2024, and a net loss of $6.3 million for the six months ended June 30, 2024.
• The company's research and development expenses were $1.6 million for the three months ended June 30, 2024, and $3.7 million for the six months ended June 30, 2024.
• General and administrative expenses were $1.1 million for the three months ended June 30, 2024, and $2.6 million for the six months ended June 30, 2024.
• As of June 30, 2024, ProMIS had cash of $0.99 million and an accumulated deficit of $99.7 million.
• In July 2024, ProMIS completed a private placement raising $30.3 million before deducting approximately $2.5 million in placement agent fees and offering costs.
• The company's lead product candidate, PMN310, completed its single ascending dose (SAD) Phase 1a clinical trial in May 2024, with topline data released in July 2024 showing it was generally well-tolerated and crossed into the central nervous system.
• A Phase 1b proof of concept trial in Alzheimers disease patients is expected to initiate in the second half of 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The successful clinical trial results and the recent financing are positive, but the ongoing losses and dependence on future funding are negative. Overall, the sentiment is cautiously optimistic.

Positives

• The PMN310 Phase 1a trial showed promising results with good tolerability and evidence of the drug reaching the central nervous system.
• The 25-day half-life of PMN310 in CSF supports a convenient once-per-month dosing schedule.
• The successful $30.3 million private placement provides significant funding to support operations into 2026.
• The company is progressing its other pipeline programs, including PMN267 for ALS and PMN442 for MSA.
• The company is advancing its vaccine programs for both amyloid and alpha-synuclein.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $99.7 million as of June 30, 2024.
• The company has not generated any revenue since its inception and does not expect to generate any revenue from product sales in the near future.
• The company is dependent on its ability to secure additional financing to continue its research and development activities.
• The company's cash balance was $0.99 million as of June 30, 2024, prior to the July 2024 private placement.

Risks

• The company is subject to the risks inherent in the development of new biopharmaceutical products, including unforeseen expenses, delays, and complications.
• The company may be unable to raise additional funds or enter into collaborations on favorable terms, or at all.
• Failure to obtain additional funding could force delays, reductions, or elimination of research and development programs.
• The company's ability to generate product revenue is dependent on the successful development and commercialization of its product candidates.
• The company's future capital requirements will depend on the timing and extent of spending on research and development and market acceptance of its products, if approved.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future and will need substantial additional funding to support its continuing operations and pursue its growth strategy. A Phase 1b proof of concept trial in Alzheimers disease patients is expected to initiate in the second half of 2024.

Management Comments

• Management believes that the net proceeds from the private placement will provide sufficient cash to continue operating and capital expenditure requirements for 12 months beyond the issuance of these unaudited condensed consolidated financial statements.
• Management believes that the net proceeds from the July 2024 private placement will provide sufficient cash, based on our current operating plan, to enable us to fund our operating expenses into 2026.

Industry Context

The company is operating in the competitive field of neurodegenerative disease therapeutics, with a focus on Alzheimers, ALS, and MSA. The company's approach of targeting misfolded proteins is aligned with current research trends in these diseases. The successful completion of the Phase 1a trial and the initiation of the Phase 1b trial are important steps in the company's development pathway.

Comparison to Industry Standards

• The company's approach of targeting misfolded proteins is consistent with the current focus of many companies in the neurodegenerative disease space, such as Biogen, Eli Lilly, and Roche.
• The company's Phase 1a trial for PMN310 is comparable to similar early-stage trials for other Alzheimers drugs, with a focus on safety and tolerability.
• The company's reported cash burn rate is typical for a clinical-stage biotech company, and the recent private placement is a common method for raising capital in this sector.
• The company's focus on multiple neurodegenerative diseases, including ALS and MSA, is a differentiator compared to companies solely focused on Alzheimers.

Related Party Transactions

• The company has a collaborative research agreement with the University of British Columbia (UBC) and the Vancouver Coastal Health Authority, with the company's Chief Scientific Officer as principal investigator at the UBC.

Stakeholder Impact

• Shareholders will be impacted by the dilution from the recent private placement and the potential for future capital raises.
• Employees will be impacted by the company's ability to secure funding and continue its research and development programs.
• Patients with neurodegenerative diseases may benefit from the company's development of new therapies.
• Creditors and suppliers will be impacted by the company's ability to meet its financial obligations.

Next Steps

• Initiate a Phase 1b proof of concept trial in Alzheimers disease patients in the second half of 2024.
• Present the full dataset from the PMN310 Phase 1a trial at an upcoming medical meeting in the second half of 2024.
• Seek shareholder approval for the exercise of Tranche A and Tranche B Common Share purchase warrants from the July 2024 private placement.
• Continue to advance the preclinical development of PMN267 for ALS and PMN442 for MSA.
• Continue to progress with other key projects, including the amyloid and alpha-synuclein vaccine programs.

Key Dates

Keywords

PMN310, Alzheimers disease, clinical trial, monoclonal antibody, neurodegenerative diseases, private placement, financing, research and development, PMN267, ALS, PMN442, MSA, amyloid-beta, TDP-43, alpha-synuclein